GlassScriptPhysician profile
Ashima Kapoor
NPI 1750811030
$5,987.15
in general payments reported to CMS, 2019-2025
53 companies · $2,743 in 2025
The $2,743 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.97 · 2020: $50.49 · 2021: $869 · 2022: $550 · 2023: $751 · 2024: $1,008 · 2025: $2,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,406 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,406.05 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $744.27 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Amgen INC. | $444.67 | 2021-2023 | Lumakras, Blincyto, Kyprolis |
| Novartis Pharmaceuticals Corporation | $319.91 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.62 | 2020-2025 | Opdivo, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $294.74 | 2024-2025 | Keytruda |
| Abbvie INC. | $276.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $223.78 | 2024-2025 | Ninlaro, Fruzaqla, Vpriv |
| Incyte Corporation | $222.33 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Gilead Sciences, INC. | $214.87 | 2024-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $212.61 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Genzyme Corporation | $212.53 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $192.53 | 2024-2025 | Onivyde |
| Celgene Corporation | $171.92 | 2021-2025 | Reblozyl, Pomalyst |
| Seagen INC. | $156.17 | 2022 | |
| Pfizer INC. | $147.18 | 2024-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $146.50 | 2022-2023 | Rybrevant, Carvykti |
| Astellas Pharma US INC | $138.05 | 2024-2025 | Padcev, Vyloy, Xospata |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.19 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $118.97 | 2022-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $118.58 | 2024-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $83.82 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $82.38 | 2022-2025 | Monoferric |
| Eisai INC. | $77.42 | 2024-2025 | |
| Exelixis INC. | $76.84 | 2022-2025 | Cabometyx |
| Genentech USA, INC. | $73.30 | 2019-2025 | Polivy, Phesgo, Itovebi |
| Array Biopharma INC | $62.51 | 2025 | Mektovi, Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $56.97 | 2023-2025 | Ojjaara, Shingrix |
| Geron Corporation | $42.41 | 2024-2025 | Rytelo |
| Genmab U.S., INC. | $40.74 | 2023-2025 | Epkinly, Tivdak |
| Lilly USA, LLC | $37.59 | 2020-2025 | Jaypirca, Retevmo, Verzenio |
| Springworks Therapeutics, INC. | $34.91 | 2025 | Ogsiveo |
| Kyowa Kirin, INC. | $34.66 | 2024-2025 | Poteligeo |
| Iovance Biotherapeutics, INC. | $33.88 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $30.46 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $29.51 | 2025 | |
| Janssen Pharmaceuticals, INC | $29.12 | 2021-2024 | Xarelto |
| Novocure INC. | $29.07 | 2021-2025 | Optune Lua (Novottf-200t) |
| Alnylam Pharmaceuticals INC. | $27.62 | 2025 | Givlaari |
| Karyopharm Therapeutics INC. | $26.10 | 2024 | Xpovio |
| Octapharma USA, INC. | $25.65 | 2021 | |
| Mirati Therapeutics, INC. | $25.00 | 2023 | Krazati |
| Apellis Pharmaceuticals, INC. | $24.49 | 2024 | Empaveli |
| Sobi, INC | $23.34 | 2025 | |
| Sun Pharmaceutical Industries INC. | $22.59 | 2025 | |
| Stemline Therapeutics INC. | $22.10 | 2022 | |
| Beone Medicines USA, INC. | $21.66 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $21.62 | 2025 | Pyrukynd |
| Puma Biotechnology, INC. | $21.55 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.75 | 2025 | |
| Syndax Pharmaceuticals, INC. | $18.57 | 2025 | |
| Allergan, INC. | $18.24 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.98 | 2025 | Myrisk |
| Caris Mpi, INC. | $14.19 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashima Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.